Leflunomide for Polyomavirus Type BK Nephropathy
- 17 March 2005
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (11) , 1157-1158
- https://doi.org/10.1056/nejm200503173521125
Abstract
Polyomavirus type BK nephropathy is an aggressively destructive disease occurring in up to 8 percent of patients with renal allografts,1,2 with rates of graft loss within one year of 30 to 65 percent.3,4 There is no therapy with proven efficacy. Leflunomide (Arava), approved for the treatment of rheumatoid arthritis, is an immunosuppressive drug, yet its active metabolite, A77 1726, has substantial antiviral activity in vitro and in animals.5Keywords
This publication has 5 references indexed in Scilit:
- Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant RecipientsNew England Journal of Medicine, 2002
- Clinical Course of Polyoma Virus Nephropathy in 67 Renal Transplant PatientsJournal of the American Society of Nephrology, 2002
- POLYOMAVIRUS DISEASE UNDER NEW IMMUNOSUPPRESSIVE DRUGSTransplantation, 1999
- HUMAN POLYOMA VIRUS-ASSOCIATED INTERSTITIAL NEPHRITIS IN THE ALLOGRAFT KIDNEY1Transplantation, 1999
- Inhibition of Cytomegalovirus in vitro and in vivo by the Experimental Immunosuppressive Agent LeflunomideIntervirology, 1999